CN101384622B - Fgf2结合肽及其用途 - Google Patents

Fgf2结合肽及其用途 Download PDF

Info

Publication number
CN101384622B
CN101384622B CN2007800033499A CN200780003349A CN101384622B CN 101384622 B CN101384622 B CN 101384622B CN 2007800033499 A CN2007800033499 A CN 2007800033499A CN 200780003349 A CN200780003349 A CN 200780003349A CN 101384622 B CN101384622 B CN 101384622B
Authority
CN
China
Prior art keywords
ptx3
peptide
fgf2
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800033499A
Other languages
English (en)
Chinese (zh)
Other versions
CN101384622A (zh
Inventor
M·普莱斯塔
M·卡莫兹
M·鲁斯纳提
M·克罗姆伯
D·马斯特罗安尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Tecnogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen SpA filed Critical Tecnogen SpA
Publication of CN101384622A publication Critical patent/CN101384622A/zh
Application granted granted Critical
Publication of CN101384622B publication Critical patent/CN101384622B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
CN2007800033499A 2006-01-24 2007-01-23 Fgf2结合肽及其用途 Expired - Fee Related CN101384622B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06001457.8 2006-01-24
EP06001457 2006-01-24
PCT/EP2007/000538 WO2007085412A1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof

Publications (2)

Publication Number Publication Date
CN101384622A CN101384622A (zh) 2009-03-11
CN101384622B true CN101384622B (zh) 2013-03-27

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800033499A Expired - Fee Related CN101384622B (zh) 2006-01-24 2007-01-23 Fgf2结合肽及其用途

Country Status (19)

Country Link
US (1) US8076300B2 (enExample)
EP (1) EP1973944B1 (enExample)
JP (1) JP5427415B2 (enExample)
KR (1) KR101467453B1 (enExample)
CN (1) CN101384622B (enExample)
AU (1) AU2007209581B2 (enExample)
BR (1) BRPI0707239A8 (enExample)
CA (1) CA2637295C (enExample)
DK (1) DK1973944T3 (enExample)
EA (1) EA015339B1 (enExample)
ES (1) ES2575517T3 (enExample)
HR (1) HRP20160600T1 (enExample)
HU (1) HUE029212T2 (enExample)
IL (1) IL192800A (enExample)
MX (1) MX2008009289A (enExample)
PL (1) PL1973944T3 (enExample)
PT (1) PT1973944T (enExample)
SI (1) SI1973944T1 (enExample)
WO (1) WO2007085412A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Catherine Perollet et al..Platelet Factor 4 Modulates Fibroblast Growth Factor 2 (FGF-2) Activity and Inhibits GFG-2 Dimerization.《blood》.1998,第91卷3289-3299. *
Marco Presta et al..Fibrolast growth factor/fibroblast growth factor receptor system in angiogenesis.《Cytokine & Growth Factor Reviews》.2005,第16卷159-178. *
Marco Rusnati et al..Marco Rusnati et al..《blood》.2004,第104卷第92-99页. *

Also Published As

Publication number Publication date
MX2008009289A (es) 2008-10-17
HRP20160600T1 (hr) 2016-07-01
KR101467453B1 (ko) 2014-12-01
CA2637295A1 (en) 2007-08-02
AU2007209581B2 (en) 2013-03-28
DK1973944T3 (en) 2016-06-27
SI1973944T1 (sl) 2016-07-29
BRPI0707239A8 (pt) 2018-01-30
ES2575517T3 (es) 2016-06-29
KR20080096794A (ko) 2008-11-03
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
JP2009523457A (ja) 2009-06-25
IL192800A (en) 2015-04-30
EA015339B1 (ru) 2011-06-30
BRPI0707239A2 (pt) 2011-04-26
HUE029212T2 (en) 2017-02-28
CN101384622A (zh) 2009-03-11
EP1973944A1 (en) 2008-10-01
PL1973944T3 (pl) 2016-09-30
PT1973944T (pt) 2016-07-07
EA200870188A1 (ru) 2009-02-27
US20090215689A1 (en) 2009-08-27
EP1973944B1 (en) 2016-05-11
WO2007085412A1 (en) 2007-08-02
CA2637295C (en) 2017-06-13
AU2007209581A1 (en) 2007-08-02
US8076300B2 (en) 2011-12-13
JP5427415B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
Yates-Binder et al. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis
Rauch et al. Neurocan: a brain chondroitin sulfate proteoglycan
Wium et al. The dual role of TAM receptors in autoimmune diseases and cancer: an overview
Ziarek et al. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery
R Mohan et al. Decorin biology, expression, function and therapy in the cornea
Parker et al. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin
UA74798C2 (uk) Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ES2284678T3 (es) Polipeptidos de claudinas.
EA024292B1 (ru) Новое антитело против ngf человека
Xu et al. LRIG1 extracellular domain: structure and function analysis
CN101384622B (zh) Fgf2结合肽及其用途
US8623832B2 (en) Peptide compositions that bind TLR-4
NZ584278A (en) Sdf-1-based glycosaminoglycan antagonists and methods of using same
CN101142234A (zh) 结合红细胞生成素受体的新肽
CN103204940A (zh) CD147-5A12MAb复合物晶体结构及应用
WO2017210598A1 (en) Compositions and methods for treating an articular disorder
Bennett et al. Ankyrins: a family of proteins that link diverse membrane proteins to the spectrin skeleton
ES2265443T3 (es) Mfq-111, una proteina similar a gtpasa humana.
Class et al. Patent application title: PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME Inventors: Shanjana Awasthi (Edmond, OK, US) Assignees: The Board of Regents of the University of Oklahoma
Jokinen Conformational Regulation of alpha2beta1 Integrin in Ligand Binding
Chen Interaction of thrombospondin 2 with cells: A comparison with thrombospondin 1
Beauvais Syndecan-1 regulates alpha (v) beta (3) and alpha (v) beta (5) integrin activity via the ectodomain of its core protein
Le Saux et al. The role of caveolin-1 in pulmonary matrix remodeling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

Free format text: FORMER OWNER: TECNOGEN S. P. A.

Effective date: 20130308

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130308

Address after: Rome Italy

Patentee after: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A.

Address before: Italy Caserta

Patentee before: Tecnogen S. P. A.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130327

Termination date: 20190123